Entera Bio Ltd (ENTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Entera Bio Ltd stock (ENTX) is currently trading at $1.18. Entera Bio Ltd PS ratio (Price-to-Sales) is 410.50. Analyst consensus price target for ENTX is $10.00. WallStSmart rates ENTX as Sell.
- ENTX PE ratio analysis and historical PE chart
- ENTX PS ratio (Price-to-Sales) history and trend
- ENTX intrinsic value — DCF, Graham Number, EPV models
- ENTX stock price prediction 2025 2026 2027 2028 2029 2030
- ENTX fair value vs current price
- ENTX insider transactions and insider buying
- Is ENTX undervalued or overvalued?
- Entera Bio Ltd financial analysis — revenue, earnings, cash flow
- ENTX Piotroski F-Score and Altman Z-Score
- ENTX analyst price target and Smart Rating
Entera Bio
📊 No data available
Try selecting a different time range
Smart Analysis
Entera Bio Ltd (ENTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Entera Bio Ltd (ENTX) Key Strengths (0)
Supporting Valuation Data
Entera Bio Ltd (ENTX) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -91.50%, a shrinking business
Very expensive at 410.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.3x book value
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Entera Bio Ltd (ENTX) Detailed Analysis Report
Overall Assessment
This company scores 13/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (410.50), Price/Book (3.34) suggest expensive pricing. Growth concerns include Revenue Growth at -91.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -99.40%, Operating Margin at -8729.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -99.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -91.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ENTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ENTX's Price-to-Sales ratio of 410.50x trades at a deep discount to its historical average of 1036.62x (54th percentile). The current valuation is 94% below its historical high of 7369.91x set in May 2024, and 621% above its historical low of 56.96x in Nov 2022.
WallStSmart Analysis Synopsis
Data-driven financial summary for Entera Bio Ltd (ENTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Entera Bio Ltd operates as a stable business with moderate growth and solid fundamentals. Revenue reached 124,000 with 92% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 1319% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 92% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Entera Bio Ltd.
Bottom Line
Entera Bio Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Entera Bio Ltd(ENTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.